Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV

Jordan Wilkins¹, Yi-Min Zheng¹, Jingyou Yu¹, Chen Liang²,³, Shan-Lu Liu¹*

¹ Department of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri, Columbia, Missouri, United States of America, ² Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada, ³ Departments of Medicine, Microbiology & Immunology, McGill University, Montreal, Quebec, Canada

* liushan@missouri.edu

Abstract

Interferon-induced transmembrane (IFITM) proteins are potent antiviral factors shown to restrict the infection of many enveloped viruses, including HIV. Here we report cloning and characterization of a panel of nonhuman primate IFITMs. We show that, similar to human IFITM, nonhuman primate IFITM proteins inhibit HIV and other primate lentiviruses. While some nonhuman primate IFITM proteins are more potent than human counterparts to inhibit HIV-1, they are generally not effective against HIV-2 similar to that of human IFITMs. Notably, depending on SIV strains and also IFITM species tested, nonhuman primate IFITM proteins exhibit distinct activities against SIVs; no correlation was found to support the notion that IFITM proteins are most active in non-natural primate hosts. Consistent with our recent findings for human IFITMs, nonhuman primate IFITM proteins interact with HIV-1 Env and strongly act in viral producer cells to impair viral infectivity and block cell-to-cell transmission. Accordingly, knockdown of primate IFITM3 increases HIV-1 replication in nonhuman primate cells. Interestingly, analysis of DNA sequences of human and nonhuman primate IFITMs suggest that IFITM proteins have been undergoing purifying selection, rather than positive selection typical for cellular restriction factors. Overall, our study reveals some new and unexpected features of IFITMs in restricting primate lentiviruses, which enhances our understanding of virus-host interaction and AIDS pathogenesis.

Introduction

Following detection of pathogen-associated molecular patterns (PAMPs), cells produce and secrete interferon [1, 2]. Interferons are cytokines that upregulate the expression of hundreds of interferon-stimulated genes (ISGs) and represent one of the cells first lines of defense against viruses [3]. Several ISGs have been characterized with antiviral activity, including Tetherin, TRIM5α, APOBEC3G, SAMHD1, and MxB [4–11]. The interferon-induced transmembrane (IFITM) proteins are a subset of ISGs known to restrict several enveloped viruses including, but not limited to, influenza A virus (IAV), dengue virus, Ebola virus, SARS coronavirus, hepatitis C virus (HCV), Jaagsiekte sheep retrovirus (JSRV) and human immunodeficiency virus (HIV) [12–19].
In humans, five IFITM isoforms have been discovered thus far [20]. IFITM5 is found in osteoblasts and functions in bone mineralization while IFITM10 has an unknown function [21, 22]. The remaining three members (IFITM1, 2, and 3) have been characterized with antiviral activity [20, 23]. The IFITM proteins are localized to both the plasma membrane and the endosomal membranes where they are thought to restrict viral entry by directly modulating cell membranes or antagonizing components of the viral structure [19, 24–29]. While the exact topology of IFITMs remains unclear, studies have suggested that the IFITMs have full or partial membrane-spanning regions, with the N-terminus and a conserved central region on the cytosolic side and the C-terminus being extracellular [26, 30, 31]. The N-terminus of human IFITM2 and IFITM3 contain an additional 20 or 21 amino acids, respectively, compared to IFITM1. This extended N-terminal region contains a tyrosine residue (Y20) that is important for IFITM localization and their antiviral activity [32–34]. Recently, the PPxY motif of IFITM3 was discovered to interact with the NEDD4 E3 ligase that causes IFITM3 ubiquitination [35]. Cysteine residues C71, C72, and C105 in IFITM3, which are also conserved in IFITM1 and IFITM2, are palmitoylated and contribute to its antiviral function [24, 31]. Two phenylalanine residues (F75 and F78) in IFITM3 mediate interaction amongst the IFITMs, increasing IFITM3 antiviral properties [36]. Interestingly, IFITM proteins have also been shown to promote infection or replication of some viruses, although the underlying mechanisms remain to be defined [37, 38].

HIV-1 and HIV-2 are the results of zoonotic transmission of SIV into humans from chimpanzee and sooty mangabey, respectively [39, 40]. Adaptation into new hosts often requires viruses to evolve countermeasures to evade new host defenses. For example, TRIM5α from rhesus monkey (TRIM5αrh) is highly effective at restricting HIV-1 [5]. However, TRIM5αrh does not restrict viruses that naturally infect Old World monkeys (SIVmac). These observations were attributed to changes in the sequence of viral capsid from SIV to HIV [5]. Similarly, human Tetherin is less effective restricting HIV when compared to that of SIV and vice versa [41]. The decreased inhibitory effects of human TRIM5α and Tetherin on HIV-1 account for efficient spread and pathogenesis of HIV-1 in humans [42].

Canonically, restriction factors are characterized by their ability to restrict viruses in non-natural hosts and have undergone positive selection due to viral antagonism. We find here that while nonhuman primate IFITM proteins are in general more potent to restrict HIV-1, they are still highly effective against some strains of SIVs derived from their own natural hosts. Moreover, phylogenetic analysis shows that primate IFITM proteins have been undergoing purifying selection, suggesting that the primary amino acid sequences of IFITMs are essential for their structure and functions, which is atypical for restriction factors.

Materials and Methods

Cells, plasmids, and reagents

SupT1 (NIH AIDS Reagent Program) and Jurkat-inGLuc (gift from Walther Mothes) cells were maintained in Roswell Park Memorial Institute medium (RPMI-1640) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. HeLa-TZM-bl (NIH AIDS Reagent Program) and HEK293T (ATCC) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS and 1% penicillin-streptomycin. Nonhuman primate fibroblasts were obtained from Coriell Institute cell repositories (Camden, NJ). Fibroblasts were either maintained in DMEM and/or Minimum Essential Medium (MEM) with 10–15% FBS and 1% penicillin-streptomycin according to Coriell’s specimen specifications. All cells were incubated in a 5% CO2 atmosphere at 37°C.
All IFITMs were cloned into the retroviral vector pQCXIP containing an N-terminal Flag tag. The following proviral DNAs were obtained from NIH AIDS Reagent Program: HIV-1-NL4.3 (#114), HIV-1 BH10 (#90), HIV-2-ROD1 (#207), SIVcpzTAN2.69 (#11497), SIVagm-TAN (#3444), and SIVmac239 (#210). The pCMV-BlaM-Vpr construct was purchased from Addgene (#21950) (described in [43]). Lentiviral vectors containing control-shRNA or IFITM3-shRNA were purchased from Sigma. The anti-FLAG beads (F2426), anti-FLAG (F3165) and anti-β-tubulin (T8328) antibodies were purchased from Sigma. Anti-IFITM3 antibody was purchased from Proteintech (11714-1-AP). The following antibodies were obtained from NIH AIDS Reagent Program: anti-HIV-1 gp120 (#288), anti-HIV-1 gp41 (#1475), and anti-HIV-1 p24 (#1513).

Cloning and DNA sequencing

Nonhuman primate IFITM genes were obtained from the following primate cell lines (Coriell Institute, Camden, NJ): gorilla (Gorilla gorilla), L’Hoest’s monkey (Cercopithecus lhoesti), moustached monkey (Cercopithecus cephus cephus), red-capped mangabey (Cercocebus torquatus torquatus), mandrill (Mandrillus sphinx), Syke’s monkey (Cercopithecus albogularis), and guereza (Colobus guereza). Briefly, the total RNAs were extracted from these non-human primate cell lines using an RNeasy kit (Qiagen). Reverse transcription was carried out by using 1 μg of total RNA, plus random primer (Thermal Fisher Scientific) and Superscript III (Invitrogen) following manufacturer’s instructions. IFITM genes were PCR amplified from cDNAs using primers IFITM1 forward/reverse (CAACAGGGGAAAGCAGGGCTC/CTGTATCTAGGGCAGGACCAAG) and IFITM3 forward/reverse (CAACACTTCTTTCCCCAAAGCCAG/TTGTGGACAGGTGTGTGGG). PCR products were cloned into PCR2.1 vector, and 3–5 clones from each species were sequenced. A Flag tag was introduced to the N termini of primate IFITMs by PCR, and the insert IFITM genes in PCR2.1 were subcloned into pQCXIP vector at BamHI and EcoRI sites. All IFITM genes on pQCXIP vector were confirmed by DNA sequencing.

Stable cell lines

SupT1 and Jurkat-inGLuc cell lines stably expressing IFITMs were produced by transduction of cells with pQCXIP-IFITM constructs [19, 29]. Briefly, HEK293T cells were seeded in 35 mm dishes and transfected with 1 μg pQCXIP-flag-IFITM, 1 μg pCMV-gag-pol-MLV, and 0.1 μg pVSV-G using calcium phosphate method. Viral supernatants were harvested over 72 hours and clarified via centrifugation. Retroviral particles were used to infect SupT1 or Jurkat-inGLuc cells in the presence of 4 μg/ml polybrene by spinoculation at 1,850 x g for 1 hour at 4°C. Stably transduced cells were selected for with 1 μg/ml puromycin.

To knockdown IFITM3 in gorilla fibroblasts (Cat #), HEK293T cells were cotransfected with pHIV-Δ8.2-Gag-Pol, lentiviral shRNA (Sigma), and VSV-G. Produced virions were used to infect gorilla fibroblast. Transduced fibroblasts were selected for with 1 μg/ml puromycin.

Viral replication assay

For HIV-1 long-term replication, 5 X 10^5 SupT1 cells were challenged with appropriate volumes of the wild type NL4.3 viral stock; unbound virus was removed 6 hours after the initiation of infection and cells were incubated with fresh RPMI-1640 medium. Supernatants containing newly produced virions were collected every 2 days until a complete cell death was observed. Supernatants were measured for viral production by performing reverse transcriptase (RT) assay (see below) and for infectivity by infecting HeLa-TZM-bl cells.
RT assay
The experiments were performed as previously described [15]. Briefly, 10 μL virions containing culture supernatants were incubated with 40 μL of reaction mixture at 37°C for 3 h. The mixture contains 50 mM Tris-HCl pH 7.9, 5 mM MgCl₂, 0.5 mM EGTA, 0.05% Triton X-100, 2% (V/V) ethylene glycol, 150 mM KCl, 5 mM DTT, 0.3 mM GSH (reduced glutathione), 0.5 U/ml poly (rA) oligo (dT), and 0.1 μCi/μL 3H dTTP (Perkin-Elmer). The reaction was stopped by adding 10% (V/V) cold Trichloroacetic Acid (TCA) at 4°C for 30 min, and the mixture was transferred to Millipore MultiScreen Glass Fiber FC plate. After being washed twice with cold 10% (V/V) TCA and cold ethanol, the membranes were inserted into Beta Gamma vials and read in Microbeta counter (Beckman Coulter).

Infectivity assay
SupT1 cells were seeded at 4 X10⁵ cells/ml in 12-well dishes. Infectious virus was added in the presence of 4 μg/ml polybrene with spinoculation at 1,850 X g for 1 hour at 4°C and then incubated at 37°C for 6 hours. SupT1 cells were then refed and incubated for an additional 48 hours. Viral supernatants were used to infect HeLa-TZM-bl cells. Forty-eight hours post-infection, HeLa-TZM-bl cells were harvested in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100). HeLa-TZM-bl lysates were mixed with an 1:1 ratio with assay buffer (200 mM Tris pH 7.8, 250 mM MgCl₂, 7.5 mM ATP, 25 mM CoA, 0.2 mg/ml D-Luciferin) and measured for luciferase activity using a Perkin Elmer plate reader.

Immunoprecipitation and western blot
HEK293T cells were cotransfected with HIV-1-NL4.3 and increasing amounts of IFITM plasmids. pQCXIP-empty was used as a control and to ensure all transfections had an equivalent amount of total plasmid during transfection. At 48 hours post-transfection, HEK293T cells were harvested in RIPA buffer (containing 0.05% SDS). Cell debris was removed by centrifugation. A fraction of the lysate was used for total input analysis by Western blot while the rest was subjected to immunoprecipitation using anti-FLAG beads. Immunoprecipitations were incubated overnight at 4°C with rotation. Beads were centrifuged and washed three times with cold lysis buffer. All samples were boiled in sample buffer prior to resolving by SDS-PAGE. The gels were transferred to polyvinylidene difluoride (PVDF) membranes and blocked in blocking solution (5% non-fat milk in PBS 0.1% Tween-20) for 1 hour at room temperature. Membranes were washed (PBS with 0.1% Tween-20) three times followed by overnight incubation with the primary antibody in blocking solution overnight at 4°C. The membranes were washed three times and incubated with secondary antibodies conjugated to HRP for 1 hour at room temperature. The blots were incubated with HRP substrate (Millipore # WBLUR0100) and bands were visualized using a Fuji Imager.

Virion fusion assay and flow cytometry
The fusion assay was performed as previously described [43]. HEK293T cells were seeded onto 60 mm plates and cotransfected with 3 μg of HIV-1-NL4.3 and 1 μg of pCMV-BlaM-Vpr; virions were harvested 48–72 h post-transfection. SupT1 cells were incubated with virus and spinoculated at 4°C for 1 hour and then further incubated at 37°C for 3 hours. SupT1 cells were resuspended in CO2-independent media and loaded with CCF2 dye according to manufacturer’s recommendations (Invitrogen). Cells were washed and incubated in CO2-independent media with 10% FBS and 0.5 μM probenecid for 16 hours at room temperature. Samples were fixed in 2% formaldehyde, washed, and resuspended in PBS. Cleaved CCF2-AM dye was
detected at Ex409/Em518 and cleaved CCF2 was detected at Ex409/Em447 using a BD Fortessa flow cytometer.

Cell-to-cell infection

For cell-to-cell infection, we followed a system previously described in [29]. Briefly, Jurkat-inGLuc cells, expressing IFITMs or not expressing IFITMs, were spinoculated at 1,850 X g with infectious virus for 1 hour at 4 °C followed by incubation at 37°C for 4 hours. Cells were then treated with 10 nM phorbol myristate acetate (PMA) for 4 hours. The Jurkat-inGLuc cells were then washed and refed for 18 hours at 37°C. The infected Jurkat-inGLuc donor cells were split in half for either cell-free or cell-to-cell infection. For cell-free infection, Jurkat-inGLuc cells were incubated for 48 hours at 37°C. Newly generated virus was used to infect SupT1 target cells for 48 hours. Media from SupT1 target cells was assayed for guassia Luciferase activity. For cell-to-cell infection, Jurkat-inGLuc cells were incubated with an equivalent number of SupT1 cells expressing or not expressing IFITMs. At 48 hours post-coculture, supernatants were assayed for guassia Luciferase activity using a Perkin Elmer plate reader.

DNA sequence alignment and selection analysis

For this study, 14 new nonhuman primate IFITM sequences were used (see under Cloning and DNA Sequencing), among which 13 are unique sequences (6 IFITM1 and 7 IFITM3) at the nucleotide level and 11 are unique sequences (4 IFITM1 and 7 IFITM3) at the amino acid level. A total of 18 nucleotide sequences were used for IFITM analysis within Datamonkey online interface (http://www.datamonkey.org/dataupload.php) and MEGA6 software [44]. Sequences were aligned using ClustalW and a phylogeny of IFITM was constructed by the Neighbor-joining method [45, 46]. Evolutionary distances were estimated using the Jukes Cantor method [47]. Confidence levels were determined using the bootstrap method with 1000 replicates and selection was determined using the Nei-Gojobori method [48].

GenBank accession numbers

The GenBank accession numbers for the cloned nonhuman primate IFITMs are KU570002-KU570015.

Results

Nonhuman primate IFITMs differentially restrict HIV

HIV has adapted various mechanisms to escape host restriction [42]. While it was previously shown that IFITMs from African green monkey (AGM) are capable of restricting both HIV-1 and SIVagm to varying degrees [49], we further sought to know if the IFITMs from additional nonhuman primates are capable of restricting HIV. To do so, we cloned IFITM1 and IFITM3 from 8 nonhuman primate cell lines belonging to the families Cercopithecidae (old world monkey; OWM) and Hominidae (hominoids), stably expressed them in the CD4+ T cell line SupT1, and tested their ability to restrict HIV (Table 1, Fig 1). SupT1 cells were infected with HIV-1 (NL4.3 or BH10) or HIV-2 bearing VSV-G in order to achieve efficient infection, and newly produced virus was harvested 48 hours later. Infectivity of newly generated virus was measured using the indicator cell line HeLa-TZM-bl (TZM-bl), which is susceptible to both CXCR4 and CCR5 tropic viruses. Against HIV-1 NL4.3, we found that both human IFITM1 and IFITM3 had less than a two-fold reduction in infectivity, similar to our previous results [50], while we found up to an approximate 5- and 10-fold reduction in infectivity for the majority of nonhuman primate IFITM1 and IFITM3 tested (Fig 1A). Against HIV-1-BH10,
human IFITM1 resulted in an approximate 4-fold reduction in infectivity while human IFITM3 caused less than a 2-fold reduction (Fig 1B), again paralleling our previous reports [15, 51]. Notably, nonhuman primate IFITM1 and IFITM3 reduced HIV-1 BH10 infectivity up to 10- and 6-fold, respectively (Fig 1B). Interestingly, against HIV-2, we found only a two-fold reduction in infectivity against almost all species of IFITMs (Fig 1C). Similar to human IFITMs [29, 32], nonhuman primate IFITMs did not significantly inhibit release of HIV-1 and HIV-2 from viral producer cells based on their RT activities (data not shown). Western blotting analysis showed that the expression levels of these nonhuman primate IFITMs were approximately comparable to their human counterparts (Fig 1D). Altogether, these results suggest that HIV-1 is strongly, but differentially, restricted by IFITMs of nonhuman primate species.

Nonhuman primate IFITMs restrict different strains of SIV

HIV-1 resulted from zoonotic transmission of SIVcpz from chimpanzee (Pan trogodytes; CPZ) to humans while HIV-2 arose from SIVsm of sooty mangabey (Cercocebus atys; SM) [39, 40, 52]. We therefore tested whether or not nonhuman primate IFITMs could also restrict different strains of SIV in SupT1 cells stably expressing individual IFITM proteins. We found that, while some nonhuman primate IFITM1 and IFITM3 (such as Gorilla, L’Hoest’s and Moustached) caused an approximate 2 to 3-fold reduction in infectivity of SIVcpz, others showed activity similar to that of humans (less than 2-fold) (Fig 2A). Against SIVmac, human IFITM1 and IFITM3 caused roughly a 2-fold reduction in infectivity while nonhuman primate IFITM1 and IFITM3 resulted in up to a 7- and 10-fold reduction, respectively (Fig 2B). The most striking differences between human and nonhuman primate IFITM restriction of SIV was found against SIVagm. While human IFITMs caused an approximate 2- to 3-fold reduction in infectivity, nonhuman primate IFITM1 and IFITM3 restricted SIVagm by up to 15 to 40-fold in infectivity (Fig 2C). Of note, the antiviral activities of IFITM1 derived from Sykes and Guereza, as well as IFITM3 derived from Mandrill, Guereza, and Mangabey, were much weaker against both SIVmac and SIVagm than IFITMs of other species, again highlighting the species-dependent antiviral activities of IFITMs.

On the basis of the degrees of inhibition, we ranked the ability of nonhuman primate IFITMs to inhibit the primate lentiviruses as SIVagm > SIVmac, HIV-1 NL4.3 > SIVcpz > HIV-2. Overall, IFITMs derived from Gorilla, L’Hoest’s, Moustached, and Sykes exhibit stronger inhibition as compared to those from Mandrill, Guereza, and Mangabey.
These results collectively suggest that HIV/SIV restriction is conserved across primate IFITMs, yet in a highly virus-strain and IFITM-species dependent manner.

Nonhuman primate IFITM proteins interact with HIV envelope

Recently, our lab demonstrated that human IFITM proteins contribute to HIV-1 restriction by antagonizing envelope protein (Env), thereby impairing viral fusion, infectivity and cell-to-cell infection [29]. We sought to ask if association of human IFITM with HIV-1 Env is conserved in OWM IFITMs. Because of its strong inhibition of HIV-1 infectivity (Fig 1), we chose L’Hoest’s IFITMs to represent OWM. We co-transfected 293T cells with HIV-1 NL4.3 and flag-tagged human or L’Hoest’s IFITMs, followed by immunoprecipitation using anti-flag beads. Both human and OWM IFITM3 proteins were capable of interacting with HIV-1 Env in a dose-dependent manner, showing that IFITM-envelope interaction has been evolutionarily conserved (Fig 3A). When we compared the band intensity ratios between immunoprecipitated HIV-1 Env gp41 and flag-IFITM3, we found an approximate 20% increase in OWM IFITM3 interaction with HIV-1 Env compared to that with human IFITM3 (Fig 3B); this was despite the relatively low levels of Env expression in the OWM IFITM3-expressing cells as compared
to cells expressing human IFITM3 (Fig 3A; see gp120 and gp41 blots). Human IFITM1 had no significant interaction HIV-1 Env (Fig 3A). Both human and OWM IFITM3 proteins inhibited the processing of Env precursor into gp120 and gp41 (Fig 3A, top panel), whereas the IFITM1 protein downregulated the expression of HIV-1 Env and Gag at higher doses of transfection (Fig 3A; see gp41 and p24 blots) similar to our recent study [29]. These results demonstrate that Env interaction with IFITMs, as well as their effects on Env processing, are evolutionarily conserved among human and nonhuman primates species and that the increased interaction between L’Hoest’s IFITM3 and HIV-1 Env somewhat correlates with the enhanced antiviral effect.

**Nonhuman primate IFITM proteins inhibit virion-cell fusion of HIV-1**

Entry of HIV-1 has previously been shown to be restricted by human IFITM proteins in target cells [15, 53]. We asked if this function was conserved in OWM IFITM. To analyze entry of HIV-1 in SupT1 cells stably expressing various primate IFITMs, we utilized the β-lactamase-Vpr (BlaM-Vpr) virion fusion assay described in [43]. HIV-1 virions were generated by cotransfecting HEK293T cells with BlaM-Vpr and HIV-1-NL4.3. Purified virus particles were used to infect SupT1 cells loaded with the BlaM-specific fluorescent substrate CCF2. Successful
HIV-1 virion entry was detected by measuring BlaM cleavage of CCF2, which shifts CCF2 fluorescence emission from 520 nm (green) to 447 nm (blue) (Fig 4A). The virion fusion assay results demonstrate that the ability of IFITM to restrict HIV-1 entry is conserved in nonhuman primate IFITMs, particularly IFITM3 (Fig 4A and 4B).

Nonhuman primate IFITM proteins potently restrict HIV cell-to-cell spread and replication

Human IFITM proteins have previously been reported to restrict HIV cell-to-cell spread and replication [28, 29]. We next asked if there were any differences between primate IFITM restriction of cell-to-cell spread of HIV-1 (Fig 5). This was important, because HIV-1 entry appeared not to be dramatically affected by the various IFITMs tested (Fig 4). We utilized a method previously described in [54] that relies on an intron-regulated guassia luciferase (inGLuc) reporter gene that is expressed upon successful HIV infection of target cells [55].
Note that this assay measures only one-round of HIV-1 infection because it is based on an HIV-1 NL4.3 lentiviral vector. Donor Jurkat-inGLuc cells, either expressing or not expressing IFITMs, were infected with HIV-1 NL4.3 bearing VSV-G; 12 h post-infection, half of the cells were used to produce virus for cell-free infection while the other half were used for co-culture with target SupT1 cells expressing or not expressing IFITMs. Human IFITMs showed the greatest restriction (7-fold decrease for IFITM3) of HIV-1 cell-to-cell spread when human IFITM was expressed in both the target and donor cells (Fig 5A–5C). Notably, while a similar trend was seen for nonhuman primate IFITMs (Fig 5A–5C), there was a 21-fold decrease in HIV-1 cell-to-cell spread when both donor and target cells expressed OWM IFITM3 (3-fold greater compared to human IFITM3) (Fig 5A). These results show that nonhuman primate IFITMs share similar, perhaps modestly enhanced, cell-to-cell restriction of HIV-1 infection as those of human IFITMs.

We next examined the effects of primate IFITMs on HIV-1 replication by performing long-term replication assays using infectious WT NL4.3. Supernatants from cell culture were harvested every two days and quantified for viral production using reverse transcriptase (RT) assay. As shown in Fig 5D, the NL4.3 replication peaked on day 10 in both empty vector and human IFITM1-expressing SupT1 cells, whereas two nonhuman primate IFITM1 delayed the peak to day 14. Of note, human IFITM1 exhibited roughly half the viral production of empty vector control, consistent with the notion that its inhibitory effect on HIV-1 NL4.3 replication is modest [29]. We also found that the L’Hoest’s OWM IFITM1 had a lower peak value compared to the gorilla counterpart (Fig 5D). When IFITM3 protein was compared, we observed a
peak shift of viral replication from day 10 to day 14 for both human and gorilla IFITM3 (Fig 5E). Strikingly, HIV-1 replication in L’Hoest’s OWM IFITM3-expressing cells did not peak even after day 18 (Fig 5E). Overall, our results demonstrate that IFITM inhibition of HIV-1 replication is evolutionarily conserved, and that nonhuman primate IFITMs are more potent to inhibit HIV-1 replication than those of human counterparts.

Knockdown of endogenous IFITM3 in gorilla fibroblasts promotes HIV-1 replication

To ensure that endogenous IFITM3 of nonhuman primate cell origin contributed to the restriction of HIV-1, we knocked down IFITM3 in gorilla fibroblasts and examined the effect on HIV-1 short-term replication (Fig 6). Gorilla IFITM3 was knocked down using a lentiviral small hairpin RNA against IFITM3. Expression of gorilla IFITM3 was reduced compared to that of a non-specific control shRNA (Fig 6A). Gorilla cells were infected with HIV-1 NL4.3 pseudotyped with VSV-G to ensure entry. After a single round of replication, supernatants containing newly generated virus were harvested and examined for RT activity and by infecting HeLa-TZM-bl cells (Fig 6B and 6C, respectively). There was more than a 2-fold increase in RT activity of viral supernatants from IFITM3 knockdown cells (Fig 6B). Consistently, the infectivity of produced virus was also increased when gorilla IFITM3 was knocked down (Fig 6C). These results support the conclusion that the ability of endogenous nonhuman primate IFITMs to restrict lentiviruses is ancestrally conserved.
IFITM proteins are under purifying selection

Analysis of protein-coding nucleotide substitutions can provide insight into the type of selective pressure on proteins over time [56]. Nucleotide substitutions that result in a change in the amino acid sequence are referred to as nonsynonymous (dN) while silent changes are considered synonymous (dS). A ratio of nonsynonymous over synonymous substitutions (dN/dS) can be used to detect for positive, neutral, or purifying selection (also referred to as negative selection) [56]. To infer what type of selective pressure the IFITM proteins were under, we analyzed 9 primate IFITM1 or 9 primate IFITM3 sequences, including those of AGM we recently described [49] using Datamonkey [57–59] (Table 2) and MEGA6 software [44] (S1 Fig). In both cases, analysis of nucleotide sequences from IFITM1 and IFITM3 showed that the values of dN were much less than dS. Expanding the primate IFITM sequences to include additional IFITMs of other species from GenBank yielded similar results (data not shown), suggesting that IFITM proteins are under purifying selection (Table 2 and S1 Fig). Taken together, these results suggest that the primary amino acid sequence of the IFITM proteins are crucial for their biological functions and that most nonsynonymous changes could be deleterious to IFITMs.

Discussion

In general, restriction factors are characterized with antiviral activity, are interferon inducible, targeted by viral antagonists, and undergo positive selection. Positive selection of restriction factors results from continual virus-host competition that occurs during infection. This effect is described by the Red Queen hypothesis, which results in an excess of non-synonymous mutations over time in both the virus and host restriction factors improving their overall fitness (positive selection). For example, the restriction factors TRIM5α, Teitherin, APOBEC3G, SAMHD1, and Viperin are all interferon inducible, restrict lentiviruses, and have undergone positive selection as a result of competing with viral antagonists [60–64].

IFITM proteins have been characterized as restriction factors as they are interferon inducible and restrict many enveloped viruses. Herein, we show that primate IFITMs have undergone purifying or negative selection suggesting that primate IFITMs are atypical restriction factors that are not directly antagonized by viruses. In this study, we determined the sequence for 14 new nonhuman primate IFITMs from Gorilla, L’Hoest’s, Moustached, Sykes, Mangabey, Mandrill, and

![IFITM proteins are under purifying selection](image-url)
Guereza and demonstrated that primate IFITMs have undergone purifying selection rather than positive selection. Negative selection of primate IFITMs would suggest they have not been highly antagonized by viruses; to date there are no known viral antagonists that directly target the IFITMs. These results may suggest that the primate IFITMs contain an ancient primary function that is not involved in viral restriction. Indeed, IFITMs have been implicated in several cellular functions including immunity, germ cell development, cell adhesion, oncogenesis, bone mineralization, proliferation and cell death [21, 65–68]. Furthermore, in the absence of IFN, IFITM proteins have been shown to be basally expressed in cells (including gorilla fibroblasts, Fig 6A) [65].

To determine if nonhuman primates conserved viral restriction, we tested their ability to restrict the primate lentiviruses HIV and SIV. Our observations show that nonhuman primate IFITMs are capable of restricting both HIV and SIV. Interestingly, some nonhuman primate IFITMs derived from OWMs appeared to be more efficient restricting both HIV and SIV compared to that of their human counterparts. For instance, IFITM3agm was more restrictive against SIVagm and HIV compared to human IFITM3, and this could be related to the conserved yet differential interactions between IFITM3 and primate lentivirus envelope proteins.

### Table 2. IFITM proteins undergo purifying selection.

| Codon | E[dS] | E[dN] | E[dN-dS] | Posterior Pr(dN>dS) | Bayes Factor (dN>dS) | Posterior Pr(dN<dS) | Bayes Factor (dN<dS) |
|-------|-------|-------|----------|---------------------|----------------------|---------------------|----------------------|
| IFITM1 |       |       |          |                     |                      |                     |                      |
| 5     | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 2196.89              |
| 6     | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 2535.89              |
| 7     | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 9062.38              |
| 15    | 2.48  | 0.47  | -2.01    | 0                   | 0                    | 1                   | 1669.77              |
| 19    | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 14377.9              |
| 26    | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 10249.7              |
| 51    | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 3188.27              |
| 56    | 2.48  | 0.22  | -2.27    | 0                   | 0                    | 1                   | 121576000            |
| 60    | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 16899.5              |
| 71    | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 17067.2              |
| 75    | 2.48  | 0.22  | -2.27    | 0                   | 0                    | 1                   | 16899               |
| 81    | 2.48  | 0.22  | -2.27    | 0                   | 0                    | 1                   | 17727.4              |
| 98    | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 25917600             |
| 102   | 2.48  | 0.23  | -2.25    | 0                   | 0                    | 1                   | 11536.9              |
| 105   | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 3956.29              |
| 106   | 2.48  | 0.22  | -2.26    | 0                   | 0                    | 1                   | 1851.16              |
| 118   | 2.44  | 0.46  | -1.98    | 0.02                | 0.01                 | 0.98                | 80.48                |
| IFITM3 |       |       |          |                     |                      |                     |                      |
| 14    | 2.05  | 0.09  | -1.96    | 0                   | 0.01                 | 1                   | 108.21               |
| 17    | 2.02  | 0.1   | -1.92    | 0                   | 0.02                 | 1                   | 59.42                |
| 29    | 2.05  | 0.1   | -1.95    | 0                   | 0.01                 | 1                   | 101.33               |
| 77    | 2.03  | 0.09  | -1.95    | 0                   | 0.01                 | 1                   | 84.3                |

Evidence of purifying selection in the primate IFITM proteins using the random-effects likelihood (REL) method assessed through the DataMonkey server (http://www.datamonkey.org). Only purifying selected sites are shown; no positive selected sites were detected. Purifying selected sites for IFITM1 and IFITM3 are indicated. A Bayes factors larger than 50 was considered significant. **Codon**: Indicates amino acid residue; **E[dS]**: Posterior mean of the synonymous substitution rate; **E[dN]**: Posterior mean of the non-synonymous substitution rate. **E[dN-dS]**: Posterior mean of the dN-dS difference; **Posterior Pr(dN>dS)**: Posterior probability for positive selection (dN>dS); **Bayes Factor (dN>dS)**: Bayes Factor (posterior odds/prior odds) for positive selection (dN>dS); **Posterior Pr(dN<dS)**: Posterior probability for negative selection (dN<dS); **Bayes Factor (dN<dS)**: Bayes Factor (posterior odds/prior odds) for negative selection (dN<dS).

doi:10.1371/journal.pone.0156739.t002
These trends may imply that some adaptations of the primate lentiviruses have occurred although it is unclear whether these are direct or indirect methods of escape. Alternatively, IFITMs have been shown to contain additional functions such as altering membrane fluidity [19]. It may be that an alternative primary function of the IFITMs indirectly affects viral entry.

When challenged against two strains of HIV-1 (NL4.3 and BH10), human IFITM1 only marginally restricted HIV-1 NL4.3 (less than 2-fold) while it had a greater restriction against HIV-1 BH10 (greater than 3-fold). These observations are in close agreement with some earlier studies [15, 50]. Furthermore, we observed that nonhuman primate IFITM1 was capable of restricting both NL4.3 and BH10 (about 5- and 6-fold reductions, respectively, Fig 1), although they did not have interaction with HIV-1 Env (Fig 3). Interestingly, we found that IFITM restriction against HIV-2 was nearly equivalent across all species of IFITM tested (about 2-fold reduction). This could suggest that certain strains of HIV-1 and HIV-2 have evolved to partially escape human IFITM restriction, though the mechanism(s) remain to be fully understood.

The IFITM proteins are capable of restricting viruses at various stages of infection [12, 13, 19, 29, 69]. We sought to determine if there was a particular stage during the HIV-1 life cycle in which nonhuman primate IFITMs inhibit HIV-1 compared to that of human IFITMs. Previously, our lab determined that human IFITMs restrict HIV-1 in part by antagonizing HIV-1 envelope [29]. In this work we found that interaction of envelope with OWM (L’Hoest’s) IFITM3 was conserved (Fig 3). However, only a slight increase (about 20%) in binding efficiency between OWM IFITM3 and HIV-1 envelope was observed (Fig 3). However, cell-to-cell transmission data clearly demonstrated that OWM IFITM3 is more efficient than human IFITM3 to reduce HIV-1 cell-to-cell spread and prolonged viral replication (Fig 5). These results together suggest that the main step of IFITM mediated restriction of HIV-1 occurs in the viral producer cells and is during cell-to-cell spread. It should be noted that the efficiency of HIV-1 cell-to-cell infection and replication in the presence of IFITMs are sometimes cell-type dependent [29].

While the various primate IFITMs are closely related and share a high degree of homology, there are several differences at the amino acid level that could account for stronger restrictive properties of some nonhuman primate IFITMs (S2 Fig). During purifying selection, changes that are deleterious to the gene function are removed from a population. In contrast, rare polymorphisms that present advantages to the population can occur and be preserved [70]. Though further investigation is needed, it is likely that polymorphisms in the IFITMs are responsible for their varying degrees of viral restriction [36, 71, 72]. It may also be that HIV/SIV Env has undergone positive selection that allows it to partially escape IFITM restriction to varying degrees [29, 51]. To date, no known viral accessory gene(s) have been identified to specifically antagonize the IFITM proteins [50], which could explain why primate IFITMs are under purifying selection. Hence, it is likely that the differential restrictions of IFITMs lie in the functional interactions between IFITM and primate lentivirus Env proteins. Indeed, we show here that human IFITMs are capable of interacting with HIV-1 envelope and that this interaction is evolutionarily conserved for OWM IFITM3 (Fig 3). More work is needed to elucidate the detailed mechanism(s) of IFITM restriction as well as viral countermeasures.

**Supporting Information**

S1 Fig. IFITM proteins are under purifying selection. (a and b) Phylogenetic trees of IFITM1 and IFITM3 genes were constructed using the Neighbor-Joining method and evolutionary distances were estimated using the Jukes-Cantor method. Bootstrap test percentages of 1000 replicates are shown next to the branches. (c and d) Selection analysis using the Nei-Gojobori method is shown. The probability of rejecting the null hypothesis dN = dS or rejecting...
dN = dS in favor of an alternative hypothesis is indicated. The test statistic is shown where the number of nonsynonymous and synonymous changes per site is represented by dN and dS, respectively. The bootstrap method using 1000 replicates was used to determine values. Analyses were conducted using MEGA6.

(TIF)

S2 Fig. Amino acid sequence alignment of human and nonhuman primate IFITM proteins used in this study. Alignment of IFITM1 proteins (left) and IFITM3 proteins (right) is shown. Sequences were aligned using ClustalW.

(TIF)

Acknowledgments

We thank Harmit Malik and Jesse Bloom at the Fred Hutchinson Cancer Research Center for helpful discussions regarding selection analysis of IFITMs.

Author Contributions

Conceived and designed the experiments: SLL CL. Performed the experiments: JW YMZ JY. Analyzed the data: SLL JW YMZ JY CL. Contributed reagents/materials/analysis tools: CL. Wrote the paper: SLL JW CL.

References

1. Ramos HJ, Gale M Jr. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol. 2011; 1(3):167–76. doi: 10.1016/j.coviro.2011.04.004 PMID: 21949557; PubMed Central PMCID: PMC3177754.

2. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Ann Rev Immunol. 2014; 32:461–88. doi: 10.1146/annurev-immunol-032713-120156 PMID: 24655297.

3. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008; 8(7):559–68. Epub 2008/06/26. nr2314 [pii] doi: 10.1038/nr2314 PMID: 18575461; PubMed Central PMCID: PMC2522268.

4. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646–50. Epub 2002/08/09. doi: 10.1038/nature00939 nature00939 [pii] PMID: 12167863.

5. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004; 427(6977):848–53. Epub 2004/02/27. doi: 10.1038/nature02343 nature02343 [pii] PMID: 14985764.

6. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res. 2009; 29(9):569–80. Epub 2009/08/22. doi: 10.1089/jir.2009.0077 PMID: 19694548; PubMed Central PMCID: PMC2956573.

7. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bossard C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011; 474(7353):654–7. Epub 2011/05/27. doi: 10.1038/nature10117 nature10117 [pii] PMID: 21613998.

8. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008; 3(4):245–52. Epub 2008/03/18. S1931-3128(08)00086-3 [pii] doi: 10.1016/j.chom.2008.03.001 PMID: 18342597; PubMed Central PMCID: PMC2474773.

9. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe. 2013; 14(4):398–410. doi: 10.1016/j.chom.2013.08.015 PMID: 24055605.

10. Kane M, Yadav SS, Bitzegeio J, Kuttuya SB, Zang T, W S.J., et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013; 502(7462):563–6.

11. Goujon C, Moncorgé O, Baulby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013; 502(7472):559–62. doi: 10.1038/nature12542 PMID: 24048477.

12. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009; 139
Restriction of Primate Lentiviruses by IFITMs

(7):1243–54. Epub 2010/01/13. S0092-8674(09)01564-5 [pii] doi: 10.1016/j.cell.2009.12.017 PMID: 2006437; PubMed Central PMCID: PMC2824905.

13. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011; 7(1):e1001258. Epub 2011/01/22. doi: 10.1371/journal.ppat.1001258 PMID: 21253575; PubMed Central PMCID: PMC3017121.

14. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol. 2010; 84(24):12646–57. Epub 2010/10/15. JVI.01328-10 [pii] doi: 10.1128/JVI.01328-10 PMID: 20943977; PubMed Central PMCID: PMC3004348.

15. Lu J, Pan Q, Rong L, Liu S-L, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol. 2011; 85(5):2126–37. doi: 10.1128/JVI.01531-10 PMID: 21177806

16. Chutwitwoonchat N, Hiyoshi M, Hiyoshi-Yoshidomi Y, Hashimoto M, Tokunaga K, Suzu S. Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins. Microbes Infect. 2013; 15(4):280–90. Epub 2013/02/05. doi: 10.1016/j.micinf.2012.03.012S1266-4579(13)00019-1 [pii] PMID: 23376165.

17. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481–5. Epub 2011/04/12. doi: 10.1038/nature09907 nature09907 [pii]. PMID: 21478670; PubMed Central PMCID: PMC3409586.

18. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, et al. Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol. 2010; 84(16):8332–41. Epub 2010/06/11. JVI.02199-09 [pii] doi: 10.1128/JVI.02199-09 PMID: 20534863; PubMed Central PMCID: PMC2916517.

19. Li K, Markosyan RM, Zheng Y-M, Golletto O, Bungart B, Li M, et al. IFITM Proteins Restrict Viral Membrane Hemifusion. PLoS Pathog. 2013; 9:e1003124.

20. Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-Family Proteins: The Cell's First Line of Antiviral Defense. Annu Rev Virol. 2014; 1:261–83. doi: 10.1146/annurev-virology-031413-085537 PMID: 25599080; PubMed Central PMCID: PMC4295558.

21. Moffatt P, Gaumond MH, Salois P, Sellin K, Bessette MC, Godin E, et al. Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res. 2008; 23(9):1497–508. Epub 2008/04/30. doi: 10.1359/jbmr.080412 PMID: 18442316.

22. Zhang Z, Liu J, Li M, Yang H, Zhang C. Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PloS One. 2012; 7(11):e49265. doi: 10.1371/journal.pone.0049265 PMID: 23166625; PubMed Central PMCID: PMC3499546.

23. Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol. 2013; 13(1):46–57. Epub 2012/12/15. doi: 10.1038/nri3344 nri3344 [pii] PMID: 23237964.

24. Yount JS, Molledo B, Yang YY, Charron G, Moran TM, Lopez CB, et al. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat Chem Biol. 2011; 7(8):610–14. Epub 2010/07/06. nchembio.405 [pii] doi:10.1038/nchembio.405 PMID: 20601941; PubMed Central PMCID: PMC2928251.

25. Weston S, Czieso S, White U, Smith SE, Kellam P, Marsh M. A membrane topology model for human interferon inducible transmembrane protein 1. PLoS One. 2014; 9(8):e104341. doi: 10.1371/journal.pone.0104341 PMID: 25103563; PubMed Central PMCID: PMC4126714.

26. Li K, Jia R, Li M, Zheng YM, Miao C, Yao Y, et al. A Sorting Signal Suppresses IFITM1 Restriction of Viral Entry. J Biol Chem. 2015; 290(7):4248–59. doi: 10.1074/jbc.M114.630780 PMID: 25527505.

27. Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell reports. 2013; 5(4):895–908. doi: 10.1016/j.celrep.2013.10.033 PMID: 24268777; PubMed Central PMCID: PMC3898084.

28. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, et al. IFITM proteins incorporated into HIV-1 viruses impair viral fusion and spread. Cell Host Microbe. 2014; 16(6):736–47. doi: 10.1016/j.chom.2014.11.001 PMID: 25464829.

29. Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, et al. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. Cell Rep. 2015; 13(1):145–56. doi: 10.1016/j.celrep.2015.08.055 PMID: 26387945; PubMed Central PMCID: PMC4602366.

30. Bailey CC, Konduhr H, Huang IC, Farzan M. Interferon-Induced Transmembrane Protein 3 is a Type II Transmembrane Protein. J Biol Chem. 2013; Sept 25, 203. Epub 9/25/2013.

31. Yount JS, Karssemeijer RA, Hang HC. S-Palmitoylation and Ubiquitination Differentially Regulate Interferon-induced Transmembrane Protein 3 (IFITM3)-mediated Resistance to Influenza Virus. J Biol
32. Jia R, Pan Q, Ding S, Liu S-L, Geng Y, Qiao W, et al. The N-terminal region of IFITM3 modulates its antiviral activity through regulating IFITM3 cellular location. J Virol. 2012; 86(24):13697–707. doi:10.1128/JVI.01828-12 PMID: 23055554

33. Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, et al. Identification of an endocytic signal essential for the antiviral action of IFIT3. Cell Microbiol. 2014. Epub 2014/02/14. doi:10.1111/cmi.12262 PMID: 24521078.

34. Chesarino NM, McMichael TM, Hach JC, Yount JS. Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem. 2014; 289(17):11986–92. doi:10.1074/jbc.M114.557694 PMID: 24627473; PubMed Central PMCID: PMC4002105.

35. Chesarino NM, McMichael TM, Yount JS. E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3. PLoS Paths. 2015; 11(8):e1005095. doi:10.1371/journal.ppat.1005095 PMID: 26263374; PubMed Central PMCID: PMC4532365.

36. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013; 87(14):7837–52. Epub 2013/05/10. doi:10.1128/JVI.00481-13 JVI.00481-13 [pii]. PMID: 23658454; PubMed Central PMCID: PMC3700195.

37. Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A. 2014; 111(18):6756–61. doi:10.1073/pnas.1320856111 PMID: 24753610.

38. Xie M, Xuan B, Shan J, Pan D, Sun Y, Shan Z, et al. Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment. J Virol. 2015; 89(6):3049–61. doi:10.1128/JVI.03416-14 PMID: 25552713; PubMed Central PMCID: PMC4337551.

39. Gao F, Bailes E, Robertson DL, Chen Y, Rodenberg CM, Michael SF, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 1999; 397(6718):436–41. doi:10.1038/17130 PMID: 9989410.

40. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature. 1989; 339(6223):389–92. doi:10.1038/339389a0 PMID: 2786147.

41. Lim ES, Malik HS, Emerman M. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol. 2010; 84(14):7124–34. doi:10.1128/JVI.00468-10 PMID: 20444900; PubMed Central PMCID: PMC2898239.

42. Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med. 2012; 2(5):a006940. Epub 2012/05/04. doi:10.1101/cshperspect.a006940 [pii]. PMID:22553496; PubMed Central PMCID: PMC3331687.

43. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002; 20(11):1151–4. PMID:12355096

44. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Bio Evol. 2013; 30(12):2725–9. doi:10.1093/molbev/mst197 PMID: 24132212; PubMed Central PMCID: PMC3840312.

45. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011; 7:539. doi:10.1038/msb.2011.75 PMID: 21988355; PubMed Central PMCID: PMC3261699.

46. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Bio Evol. 1987; 4(4):406–25. PMID: 5406447.

47. Jukes TH. Recent advances in studies of evolutionary relationships between proteins and nucleic acids. Space Life Sci. 1969; 1(4):469–90. PMID: 5406447.

48. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Bio Evol. 1986; 3(5):418–26. PMID: 3444111.

49. Qian J, Le Duff Y, Wang Y, Pan Q, Ding S, Zheng YM, et al. Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. Virology, 2015; 474:10–8. doi:10.1016/j.virol.2014.10.015 PMID: 25463599.

50. Jia R, Ding S, Pan Q, Liu SL, Qiao W, Liang C. The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PLoS One. 2015; 10(3):e0118794. doi:10.1371/journal.pone.0118794 PMID: 25738301; PubMed Central PMCID: PMC4349745.
51. Ding S, Pan Q, Liu SL, Liang C. HIV-1 mutates to evade IFITM1 restriction. Virology. 2014;454–455:11–24. doi: 10.1016/j.virol.2014.01.020 PMID: 24725927; PubMed Central PMCID: PMC4274668.

52. Sharp PM, Hahn BH. The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci. 2010; 365(1552):2487–94. doi: 10.1098/rstb.2010.0031 PMID: 20643738; PubMed Central PMCID: PMC2935100.

53. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology. 2014;11(1):103. doi: 10.1186/s12977-014-0103-y PMID: 25422070; PubMed Central PMCID: PMC4274668.

54. Agosto LM, Zhong P, Munro J, Mothes W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Paths. 2014; 10(2):e1003982. doi:10.1371/journal.ppat.1003982 PMID: 24586176; PubMed Central PMCID: PMC3937346.

55. Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Paths. 2010; 6(2):e1000788. Epub 2010/03/03. doi:10.1371/journal.ppat.1000788 PMID: 20195464; PubMed Central PMCID: PMC2829072.

56. Nei M. Selectionism and neutralism in molecular evolution. Mol Bio Evol. 2005; 22(12):2318–42. doi: 10.1093/molbev/msi242 PMID: 16120807; PubMed Central PMCID: PMC1513187.

57. Delport W, Poon AF, Frost SD, Kosakovsky Pond SL. Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics. 2010; 26(19):2455–7. doi:10.1093/bioinformatics/btq429 PMID: 20671151; PubMed Central PMCID: PMCPMC2944195.

58. Pond SL, Frost SD. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics. 2005; 21(10):2531–3. doi:10.1093/bioinformatics/bti320 PMID: 15713735.

59. Kosakovsky Pond SL, Frost SD. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Bio Evol. 2005; 22(5):1208–22. doi:10.1093/molbev/msi105 PMID: 15703242.

60. Sawyer SL, Wu Li, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A. 2005; 102(8):2832–7. Epub 2005/02/04. 0409853102 [pii] doi:10.1073/pnas.0409853102 PMID: 15689398; PubMed Central PMCID: PMCPMC49489.

61. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Paths. 2009; 5(2):e1000300. Epub 2009/02/14. doi:10.1371/journal.ppat.1000300 PMID: 19214216; PubMed Central PMCID: PMC2633611.

62. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004; 2(9):E275. doi:10.1371/journal.pbio.0020275 PMID: 15269786; PubMed Central PMCID: PMCPMC479043.

63. Wu Y, Koharudin LM, Mehrens J, DeLucia M, Byeon CH, Byeon IJ, et al. Structural Basis of Clade-specific Engagement of SAMHD1 (Sterile alpha Motif and Histidine/Aspartate-containing Protein 1) Restriction Factors by Lentiviral Viral Protein X (Vpx) Virulence Factors. J Biol Chem. 2015; 290(29):17935–45. doi:10.1074/jbc.M115.665513 PMID: 26045556; PubMed Central PMCID: PMC4505041.

64. Helbig KJ, Beard MR. The role of viperin in the innate antiviral response. J Mol Biol. 2014; 426(6):1210–9. doi:10.1016/j.jmb.2013.10.019 PMID: 24157441.

65. Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H, Tam PP. IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev Cell. 2005; 9(6):745–56. doi:10.1016/j.devcel.2005.01.010 PMID: 16326387.

66. Brem R, Oraszlan-Szovik K, Foser S, Bohrmann B, Certa U. Inhibition of proliferation by 1-8U in interferon-alpha-responsive and non-responsive cell lines. Cell Mol Life Sci. 2003; 60(6):1235–48. doi: 10.1007/s00018-003-3016-9 PMID: 12861389.

67. Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, et al. The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. Int J Cancer. 2009; 125(12):2810–9. doi:10.1002/ijc.24669 PMID: 19544527.

68. Evans SS, Collea RP, Leasure JA, Lee DB. IFN-alpha induces homotypic adhesion and Leu-13 expression in human B lymphoid cells. J Immunol. 1993; 150(3):736–47. PMID: 8423337.

69. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 Restricts Influenza A Virus Entry by Blocking the Formation of Fusion Pores following Virus-Endosome Hemifusion. PLoS Paths. 2014; 10(4):e1004048. doi: 10.1371/journal.ppat.1004048 PMID: 24699674; PubMed Central PMCID: PMC3974867.
70. Daugherty MD, Malik HS. Rules of engagement: molecular insights from host-virus arms races. Ann Rev Genet. 2012; 46:677–700. doi:10.1146/annurev-genet-110711-155522 PMID: 23145935.

71. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012; 484(7395):519–23. Epub 2012/03/27. nature10921 [pii] doi:10.1038/nature10921 PMID: 22446628.

72. Mills TC, Rautanen A, Elliott KS, Parks T, Naranbhai V, leven MM, et al. IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis 2014; 209(7):1028–31. doi:10.1093/infdis/jit468 PMID: 23997235; PubMed Central PMCID: PMC3952664.